Coronary revascularization: an opportunity for lipid screening and treatment.

[1]  T. Pearson,et al.  The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. , 2000, Archives of internal medicine.

[2]  D. Waters,et al.  Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin versus Revascularization Treatment Investigators. , 1999, The New England journal of medicine.

[3]  E. Poehlman,et al.  Lipid lowering in the cardiac rehabilitation setting. , 1999, Journal of cardiopulmonary rehabilitation.

[4]  R. Collins,et al.  Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. , 1998, The New England journal of medicine.

[5]  S. Zyzanski,et al.  Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. , 1998, Circulation.

[6]  M. Bala,et al.  Treatment patterns and distribution of low-density lipoprotein cholesterol levels in treatment-eligible United States adults. , 1998, The American journal of cardiology.

[7]  R L Brown,et al.  Primary care practice adherence to National Cholesterol Education Program guidelines for patients with coronary heart disease. , 1998, Archives of internal medicine.

[8]  D. Bramlet,et al.  Management of hypercholesterolemia: practice patterns for primary care providers and cardiologists. , 1997, The American journal of cardiology.

[9]  Bittner,et al.  Adherence to National Cholesterol Education Program Treatment goals in postmenopausal women with heart disease. The Heart and Estrogen/Progestin Replacement Study (HERS). The HERS Research Group. , 1997, JAMA.

[10]  D Blumenthal,et al.  Variations in cholesterol management practices of U.S. physicians. , 1997, Journal of the American College of Cardiology.

[11]  B. Davis,et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. , 1996, The New England journal of medicine.

[12]  R. Stables,et al.  CABG v PTCA in multi-vessel disease: angiographic insights. , 1996, European heart journal.

[13]  K. Feingold,et al.  Inadequate treatment with HMG-CoA reductase inhibitors by health care providers. , 1996, The American journal of medicine.

[14]  L. Keilson,et al.  Direct measurement of serum low-density lipoprotein cholesterol in patients with acute myocardial infarction on admission to the emergency room. , 1996, The American journal of cardiology.

[15]  R. Rosenson,et al.  Myocardial injury: the acute phase response and lipoprotein metabolism. , 1993, Journal of the American College of Cardiology.